Dalfampridine Tablet, Film Coated, Extended Release
Product Images NDC 65862-863

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Dalfampridine (NDC 65862-863). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Dalfampridine Fig1)

This is a description of the results obtained from study/trial number 1, in which the average change in walking speed was measured during a double-blind phase. The data is presented in Figure 1 as a graph that shows the average percent increase in walking speed from baseline. The placebo group, consisting of 72 participants, is represented by the "0%" bar. The "D st tables 10 mg b.id" group, consisting of 224 participants, is represented by the "%" bars ranging from 20-60%.*

FDA Label Image

Figure 2 (Dalfampridine Fig2)

FDA Label Image

Package Label-principal Display Panel (10 mg (60 Tablets Bottle))

This is a medication named Dalfampridine, available in extended-release tablets of 10 mg each. The tablets are film-coated and should not be divided, crushed, chewed or dissolved. The dispenser is required to provide a medication guide to each patient separately. The manufacturer is Aurobindo Pharma USA, Inc. Each package contains 60 tablets and should be stored in a container with a child-resistant closure at a temperature of 20° to 25°C (68° to 77°F). The package insert should be consulted for dosage instructions. The medication is available only with a prescription.*

FDA Label Image

Chemical Structure (Dalfampridine Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.